Highly sensitive biomarker panels
Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNFα, IL-17a) biomarkers provided a sensitivity of 94% for association with CHF.
1. A method for detecting cardiomyocyte damage in a subject, comprising detecting Troponin-I (cTnI), Interleukin 6 (IL-6), Interleukin 17a (IL-17a) and at least one additional biomarker in a sample from the subject, wherein the at least one additional biomarker is selected from the group consisting of B-type Natriuretic Peptide (BNP), proBNP and NT-proBNP, and Tumor Necrosis Factor alpha (TNF-α), and wherein the limit of detection of at least one of the cTnI, IL-6, IL-17A, and the at least one additional biomarker is less than about 20 pg/ml.
2. The method of claim 1 , wherein the detection of the at least one of the cTnI, IL-6, IL-17A and the at least one additional biomarker having the limit of detection less than about 20 pg/ml comprises contacting the sample with a label for the marker and detecting the presence or absence of the label wherein detection of the presence of the label indicates the presence of the corresponding marker.
3. The method of claim 2 , wherein the label comprises a fluorescent moiety, and the at least one biomarker having the limit of detection less that about 20 pg/mL is detected in an interrogation space comprising a label corresponding to a single molecule of the biomarker.
4. The method of claim 2 , wherein the label comprises a fluorescent moiety, and the detection comprises passing the label through a single molecule detector, wherein the single molecule detector comprises:
(a) an electromagnetic radiation source for stimulating the fluorescent moiety;
(b) an interrogation space for receiving electromagnetic radiation emitted from the electromagnetic source; and
(c) an electromagnetic radiation detector operably connected to the interrogation space for determining an electromagnetic characteristic of the stimulated fluorescent moiety.
5. The method of claim 1 , wherein the limit of detection of the at least one of cTnI, IL-6 and IL-17A and the at least one additional biomarker ranges from about 10 pg/ml to about 0.01 pg/ml.
6. A method to detect cardiomyocyte damage in a subject, comprising measuring a physiological biomarker and detecting Troponin-I (cTnI), Interleukin 6 (IL-6), Interleukin 17a (IL-17a) and at least one additional biomarker in a blood sample from the subject, wherein the at least one additional biomarker is selected from the group consisting B-type Natriuretic Peptide (BNP), proBNP, NT-proBNP, and Tumor Necrosis Factor alpha (TNF), and wherein the limit of detection of at least one of the cTnI, IL-6, IL-17a, and the at least one additional biomarker is less than about 20 pg/ml.
7. The method of claim 6 , wherein the physiological biomarker is a stress test.
8. The method of claim 6 , wherein the physiological biomarker is a sleep test.
9. The method of claim 6 , wherein the physiological biomarker is Carotid intima-media thickness (CIMT).
10. The method of claim 6 , wherein the physiological biomarker is Carotid intima-media thickness (CIMT).
11. A method for detecting congestive heart failure in a subject, comprising detecting whether one or more members of a panel of biomarkers comprising Troponin-I (cTnI), Interleukin 6 (IL-6) and at least one additional biomarker are elevated compared to the level of the Troponin-I (cTnI), Interleukin 6 (IL-6), Interleukin 17a (IL-17a), and at least one additional biomarker in a normal population, wherein the at least one additional biomarker is selected from the group consisting of B-type Natriuretic Peptide (BNP), proBNP, NT-proBNP, and Tumor Necrosis Factor alpha (TNF-α), and wherein the limit of detection of at least one member of the panel is less than about 20 pg/ml.
12. The method of claim 11 , wherein the at least one member of the panel having a detection limit less than about 20 pg/ml is cTnI.
13. The method of claim 11 , wherein the detection of the at least one member of the panel having the limit of detection less than about 20 pg/ml comprises contacting the sample with a label for the marker and detecting the presence or absence of the label, wherein detection of the presence of the label indicates the presence of the corresponding marker.
14. The method of claim 11 , wherein the label comprises a fluorescent moiety, and the at lease one biomarker having the limit of detection less that about 20 pg/nl is detected in an interrogation space comprising a label corresponding to a single molecule of the biomarker.
15. The method of claim 11 , wherein the label comprises a fluorescent moiety, and the detection comprises passing the label through a single molecule detector, wherein the single molecule detector comprises:
(a) an electromagnetic radiation source for stimulating the fluorescent moiety;
(b) an interrogation space for receiving electromagnetic radiation emitted from the electromagnetic source; and
(c) an electromagnetic radiation detector operably connected to the interrogation space for determining an electromagnetic characteristic of the stimulated fluorescent moiety.
16. The method of claim 15 , wherein the limit of detection of at least one member the panel ranges from about 10 pg/ml to about 0.01 pg/ml.
17. The method of claim 1 , wherein the limit of detection of cTnI, IL-6 and IL-17A, and the at least one additional biomarker is less than about 20 pg/ml.
18. The method of claim 6 , wherein the limit of detection of cTnI, IL-6 and IL-17A is less than about 20 pg/ml.
19. The method of claim 11 , wherein the limit of detection of cTnI, IL-6 and IL-17A is less than about 20 pg/ml.